Prevention: Targeted therapy - Anastrozole prevents breast cancer

Nature Reviews Clinical Oncology

Volumn 11, Issue 3, 2014, Pages 127-128

  Brown, Powel ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTHRALGIA; ARTICLE; ATYPICAL DUCTAL HYPERPLASIA; BREAST CANCER; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; INTRADUCTAL CARCINOMA; JOINT STIFFNESS; MOLECULARLY TARGETED THERAPY; MUSCULOSKELETAL DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; VAGINA DISEASE; VASOMOTOR DISORDER;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NITRILES; POSTMENOPAUSE; TRIAZOLES;

EID: 84896699527     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.17     Document Type: Article

References (10)

1. Cuzick, J. et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140- 6736(13)62292-8.
2. Cuzick, J. et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381, 1827-1834 (2013).
3. Vogel, V. G. et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295, 2727-2741 (2006).
4. Vogel, V. G. et al. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev. Res. 3, 696-706 (2010).
5. LaCroix, A. Z. et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J. Natl Cancer Inst. 102, 1706-1715 (2010).
6. Powles, T. J. et al. Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res. Treat. 134, 299-306 (2012).
7. Goss, P. E. et al. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med. 364, 2381-2391 (2011).
8. Henry, N. L. et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J. Clin. Oncol. 30, 936-942 (2012).
9. Hartmann, L. C. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340, 77-84 (1999). (Pubitemid 29054841)
10. Den Hollander, P., Savage, M. I. & Brown, P. H. Targeted therapy for breast cancer prevention. Front. Oncol. 3, 250 (2013).